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C-terminal domainA1/Bﬂ-1 is a NF-κB dependent, anti-apoptotic Bcl-2 family member that contains four Bcl-2 homology domains
(BH) and an amphipathic C-terminal domain, and is expressed in endothelial cells (EC). Based on NF-κB reporter
assays in bovine aortic EC, we have previously demonstrated that A1, like Bcl-2 and Bcl-xL, inhibits NF-κB activa-
tion. These results, however, do not fully translate when evaluating the cell's own NF-κB machinery in human EC
overexpressing A1 bymeans of recombinant adenovirus (rAd.) mediated gene transfer. Indeed, overexpression of
full-lengthA1 in humanumbilical veinEC (HUVEC), andhumandermalmicrovascular EC (HDMEC) failed to inhib-
it NF-κB activation. However, overexpression of a mutant lacking the C-terminal domain of A1 (A1ΔC) demon-
strated a potent NF-κB inhibitory effect in these cells. Disparate effects of A1 and A1ΔC on NF-κB inhibition in
human EC correlated with mitochondrial (A1) versus non-mitochondrial (A1ΔC) localization. In contrast, both
full-length A1 and A1ΔC protected EC from staurosporine (STS)-induced cell death, indicating that mitochondrial
localizationwas not necessary for A1's cytoprotective function in human EC. In conclusion, our data uncover a reg-
ulatory role for the C-terminal domain of A1 in human EC: anchoring A1 to the mitochondrion, which conserves
but is not necessary for its cytoprotective function, or by its absence freeing A1 from the mitochondrion and
uncovering an additional anti-inﬂammatory effect.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
A1, also known as Bﬂ-1, is a Bcl-2 family member originally identi-
ﬁed in hematopoietic cells, where it is abundantly expressed in re-
sponse to treatment with granulocyte-macrophage colony stimulating
factor [1]. Initially described as a hematopoietic-speciﬁc gene, A1 is
also expressed in tumors including gastrointestinal and hematopoieticA1ΔC, mutant lacking the C-termina
1/Bﬂ-1; BH, Bcl-2 homology domain
ivated cell sorting; HA, hemagglutini
dhesion molecule-1; IHC, immunoh
tant with deletion of the BH4 domai
g A1mutantwith deletion of the C-te
us β-galactosidase; RLU, relative ligh
nscription polymerase chain reactio
dical Center, Harvard Medical Schoo
Avenue, Boston, MA 02215, USA. T
an).
o, Brazil.
atology Johns Hopkins Hospital, B
, NC, USA.
rights reserved.[2,3]. Additionally, it is upregulated in response to inﬂammatory stimuli
in numerous cell types such as endothelial cells (EC) [4,5], renal proxi-
mal tubular epithelial cells (RPTEC) [6], and pancreatic beta cells [7].
Based on NF-κB reporter assays in bovine aortic EC (BAEC), we
have previously demonstrated that A1, like Bcl-2 and Bcl-xL, inhibits
NF-κB activation [5,8], and hence could have anti-inﬂammatory func-
tions in EC [9]. A1 is either not expressed or expressed at very lowl domain of A1; A1ΔΔ, Deletion of the C-terminal and BH4 domains; ANOVA, analysis of
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inﬂammatory stimuli in a NF-κB-dependent manner. Accordingly, A1
could possibly qualify as part of the anti-inﬂammatory and cytoprotective
regulatory response of EC to injury [5,10].
Homology between A1 and Bcl-2 was extensively studied. Currently,
it is recognized that A1 contains four Bcl-2 homology domains (BH1,
BH2, BH3 and BH4) and an amphipathic tail anchoring peptide in its
C-terminal domain that directs its binding to mitochondria, even if this
domain is not a bona ﬁde transmembrane domain like in other anti-
apoptotic Bcl-2 family members [11–13]. This structural conﬁguration,
particularly the BH4 domain and the C-terminal mitochondria-
anchoring domain, appears crucial for the anti-apoptotic function of
Bcl-2 family members [8,11,12,14–16]. In EC, we showed that the
BH4 domain of Bcl-2 and Bcl-xL is also key for their NF-κB inhibitory
function [8]. However, the role of the C-terminal domain in supporting
Bcl-2, Bcl-xL, or A1's NF-κB inhibitory function in EC is still not fully
elucidated.
The goals of this study were to evaluate the contribution of the
C-terminal domain of A1 to its anti-inﬂammatory function in EC, and to
extend our ﬁndings to human EC. Our results indicate that full-length
A1 has no anti-inﬂammatory effect in human EC, contrasting with
what we had reported in BAEC, when using transfection based NF-κB re-
porter assays. However, the A1 deletion mutant lacking the C-terminal
domain (A1ΔC) showed NF-κB inhibitory effect in human EC. We
reproduced these data in rAd.A1 and rAd.A1ΔC transduced BAEC,
which indicated that discrepancies in results related to differences in ex-
perimental systems used. Both full-length A1 and A1ΔC protected
human EC from cell death, indicating that mitochondrial localization
was not necessary for the cytoprotective function of this protein, at
least in this context. Together these data resolve an important regulatory
role for the C-terminal domain of A1 in EC, including in human primary
EC cultures. It also cautions extrapolating results from reporter-based
assays without evaluating the modulation of gene expression in the
context of the cell's own signaling machinery and DNA/chromatin
accessibility.
2. Material and methods
2.1. Cell culture
Human umbilical vein EC (HUVEC) were purchased from Genlantis
PrimaPure (SanDiego, CA) and cultured according tomanufacturer's in-
structions. Human dermal microvascular EC (HDMEC) and BAEC were
isolated in our laboratory and cultured as described [17,18]. The Burkitt
lymphoma cell line, BJAB was a kind of Dr. R. Khosravi-Far, and the
human hepatoma cell line HepG2was purchased fromATCC (Manassas,
VA). Cells were grown at 37 °C in a 5% humidiﬁed CO2 atmosphere.
Experiments using EC were performed on conﬂuent cells between
passages 5 and 9 (BAEC), 5 and 7 (HDMEC), and 4 and 5 (HUVEC).
2.2. Expression plasmids
The N-terminal hemagglutinin A (HA)-tagged human A1 expres-
sion plasmid was previously constructed in our laboratory [5]. This
construct was subcloned in the pAC.CMV-pLpASR + (pAC) expres-
sion plasmid to generate recombinant adenovirus (rAd.), as previous-
ly described [19]. A1 deletion mutants were generated as follows:
deletion of the C-terminal domain (A1ΔC) was achieved, with HA
tagged A1 cDNA as template, by reverse transcription polymerase
chain reaction (RT-PCR) using the following primers: sense: 5′-CGCGG
GGTACCCCATGTATCCTTATGATGTT-3′ and anti-sense: 5′-CCCCAAGCTT
GGTTACATCCAGCCAGATTTAGG-3′. Deletion of the BH4 domain
(A1ΔBH4)was performed by site-directedmutagenesis based on overlap
extension [20], using the following primers: RT-PCR reaction 1— Sense A:
5′-CGCGGGGTACCCCATGTATCCTTATGATGTT-3′ andAnti-sense B: 5′-TTC
CACTTCTTTAGGTTGTGGTATCTGTAGGAC-3′; RT-PCR reaction 2 — SenseC: 5′-CCACAACCTAAAGAAGTGGAAAAGAATCTGAAG-3′ and Anti-sense
D: 5′-CCCCAAGCTTGGTCAACAGTATTGCTTCA-3′. Deletion of the
C-terminal and BH4 domains (A1ΔΔ) was achieved by RT-PCR using
A1ΔBH4 cDNA as template and the same primers previously em-
ployed to generate A1ΔC. RT-PCR productswere veriﬁed by sequencing,
and cloned in the CMV promoter driven pAC expression plasmid. Ex-
pression of HA-tagged transgenes was veriﬁed in transfected BAEC, as
shown in the results section. All primers used for cloning were pur-
chased from Gibco, Life Technologies (Grand Island, NY).
2.3. Recombinant adenoviruses
Recombinant adenoviral vectors encoding hemagglutinin A (HA)-
tagged human A1 (rAd.A1) and A1ΔC (rAd.A1ΔC) were generated in
our laboratory, as described [19]. The control adenoviral vector
encoding nuclear β-galactosidase (rAd.βgal) was a kind gift of Dr. R.
Gerard (University of Texas, Southwestern Medical Center). Recombi-
nant adenoviruses were produced in the human embryonic 293 kidney
cell line (HEK 293, American Type Culture Collection, Rockland, MD),
extracted and puriﬁed using the Adenopure kit (Puresyn, Inc., Malvern,
PA) and tittered by limiting dilution on 293 cells, as described [19].
Pre-conﬂuent (80–90%) human EC were transduced with a multiplicity
of infection (MOI) of 200 plaque-forming units per cell (pfu/cell), while
BAEC were transduced at aMOI of 1000 pfu/cell that we have shown to
achieve transgene expression in more than 95% of EC, without causing
toxicity, and within 48 h of transduction [19].
2.4. Immunoﬂuorescence staining
Human EC cultured on glass coverslips were transduced with
rAd.βgal, rAd.A1 or rAd.A1ΔC. Forty-eight hours after transduction,
cells were labeled with 100 nM Mitotracker Red CMXRos, following
the manufacturer's instruction (Invitrogen, Molecular Probes, Carls-
bad, CA), then incubated with rat monoclonal anti-HA-ﬂuorescein an-
tibody (Roche Diagnostics, Indianapolis, IN) O/N at 4 °C. Cells were
then washed and mounted on glass slides. Images were obtained
using an Olympus BX41 microscope connected to a DP72 digital cam-
era, using 100× oil immersion objective.
2.5. Protein extraction and Western blot analysis
Total protein cell lysates were recovered from EC before, and at differ-
ent times after treatmentwith human recombinant tumor necrosis factor
(TNF) (R&D Systems, Minneapolis, MN). Protein cell lysates were ana-
lyzed byWestern blot (WB), as described [21], using the following prima-
ry antibodies: rabbit anti-IκB-α IgG, mouse anti-β-actin IgG1 (Santa Cruz
Biotechnology, Inc., Santa Cruz, CA), rat anti-hemagglutininA (HA)mono-
clonal antibody (RocheMolecular Biochemicals, Indianapolis, IN). Donkey
anti-rabbit- or goat anti-mouse-HRP-conjugated antibodies (Thermo Sci-
entiﬁc, Rockford, IL) were used as secondary antibodies. Protein bands
were detectedwith enhanced chemiluminescence kit (ECL) (PerkinElmer
Life Science, Waltham, MA), followed by exposure to autoradiography
ﬁlms.
2.6. Analysis of intercellular adhesion molecule-1 (ICAM-1) expression
by ﬂuorescence-activated cell sorting (FACS)
Forty-eight hours after rAd. transduction, EC were treated with
TNF (200 U/ml) overnight, then recovered and incubated for 30 min
in FACS buffer (0.5% BSA in PBS), followed by 1 h incubation with
FITC-conjugated mouse anti-human ICAM-1 IgG (eBioscence, Inc.,
San Diego, CA) or a control isotype IgG1 (BD Pharmingen, San Jose,
CA) at room temperature in the dark. Cells were then washed, ﬁxed
in 2% paraformaldehyde, and evaluated for surface expression of
ICAM-1 by ﬂow cytometry (FACSCanto; BD, Franklin Lakes, NJ). Re-
sults were analyzed using FlowJo software (Tree Star Inc., Ashland,
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considering βgal-transduced cells as control (100%).
2.7. Analysis of cell death
To induce cell death, we treated HUVEC and HDMEC, 48 h after rAd.
transduction, with 100 nM staurosporine (Sigma-Aldrich, St Louis, MO)
for 6 h. Cells were then collected, washed, ﬁxed in cold 70% ethanol,
and stained with propidium iodide buffer (200 μL PBS, 0.1% Triton
X-100, 0.1 mmol/L EDTA, 50 μg/mL RNAse and 50 μg/mL propidium
iodide) for 1 h in the dark. DNA content analysis was then conducted
using a FACScan bench top model (Becton Dickinson, San Jose, CA)
with Cellquest acquisition and analysis software (Becton Dickinson,
San Jose, CA). Cells with a normal DNA content (at least diploid [2N])
were scored as viable, whereas cells with a hyplodiploid DNA content
(lower than 2N) were scored as nonviable.
2.8. NF-κB luciferase reporter assay
BAEC were co-transfected with the different expression plasmids
encoding for A1, its mutants or the empty control plasmid, pAC
(0.7 μg/well), together with a NF-κB luciferase reporter plasmid
(0.6 μg/well) comprising 4 NF-κB binding sites derived from the pig
E-selectin promoter, as described [17]. Rous SarcomaVirus (RSV)-β-ga-
lactosidase reporter plasmid (RSV-βgal, 0.3 μg/well)was co-transfected
with the two other plasmids to correct for transfection efﬁciency. Trans-
fection of BAEC was achieved using cationic liposome-mediated gene
transfer (Lipofectamine, Gibco, Life Technologies, Grand Island, NY), as
described [17]. BAEC were stimulated 48 h after transfection with TNF
(200 U/mL), harvested 7 h later and assayed forβ-galactosidase and lu-
ciferase activities, as described [17]. Luciferase activity was normalized
for βgal by using the formula: luciferase activity/βgal activity ×1000.
Normalized luciferase activity is given in relative light units (RLU).
2.9. Statistical analysis
Statistical analysis was performed on Prism 5 for Mac (GraphPad
software, Inc., La Jolla, CA, USA). Data were analyzed by one-wayFig. 1. (A) Schematic representation of the sequences of HA-tagged full-length human A1
A1ΔBH4 (20.1 kDa) — A1 mutant with a deletion of the BH4 domain, and A1ΔΔ (17.8 kDa)
in pAC plasmids. (B) Expression of A1 and A1mutants in bovine aortic endothelial cells (BAEC) f
analysis using anti-HA antibody. Molecular weight markers are labeled on the left side of the ﬁanalysis of variance (ANOVA) followed by post-hoc Tukey test. Differ-
ences between groups were rated signiﬁcant at a probability error (P)
of less than 0.05. Results are presented as means ± standard error of
mean (SEM).
3. Results
3.1. Generation of A1 deletion mutants
In order to perform structure/function analysis of A1 in EC, we gener-
ated A1 mutants with deletions of the C-terminal domain (pAC.A1ΔC),
the BH4 domain (pAC.A1ΔBH4) or both (pAC.A1ΔΔ) (Fig. 1A). All A1
mutants were HA-tagged and cloned in the pAC expression plasmid,
allowing for subsequent generation of recombinant adenoviruses
(rAd.) [19]. All mutants were conﬁrmed by DNA sequencing (Core Labo-
ratory of Boston University). We subsequently transfected BAEC with
0.7 μg of full length A1 or the above-described A1-deletion mutant plas-
mids, and evaluated expression of the different transgenes by Western
blot (WB) analysis using anti-HA antibody. Our data showed that all
mutants were expressed and migrated at their expected molecular size
(Fig. 1B). Maximal transgene expression occurred 48 h after transfection
(data not shown).
3.2. Subcellular localization of A1 and A1ΔC in human EC using recombinant
adenovirus-mediated gene transfer
To evaluate the role of A1 and its mutant harboring a deletion in the
C-terminal domain in human EC, we generated rAd. expressing A1 and
A1ΔC. rAd-mediated gene transfer usually achieves signiﬁcant expres-
sion of the transgene in over 95% of transduced EC, and therefore over-
comes the limitation of inefﬁcient transfection systems in these cells.
Following veriﬁcation of rAd.A1 and rAd.A1ΔC by sequencing, we
evaluated the expression of these transgenes in human EC cultures by
immunohistochemistry (IHC), using anti-HA antibody. Our results con-
ﬁrmed that the different transgenes were expressed in >95% of trans-
duced EC (data not shown). Since subcellular localization of proteins
is difﬁcult by IHC, we performed co-immunoﬂuorescence staining and
showed that full-length A1 mostly co-localizes with mitotracker red in(22 kDa), A1ΔC (19.8 kDa) — A1 mutant with a deletion of the C-terminus domain,
— A1 mutant with a deletion of the C-terminus and the BH4 domains that were cloned
ollowing their transfectionwith the respective plasmids, as demonstrated byWestern blot
gures.
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dria (Fig. 2A and B). This supports previous data reportingmitochondri-
al localization of A1 in different cell types [22,23]. In contrast, A1ΔC did
not co-localize withmitotracker red, instead it showed diffuse cytosolic
distribution and some nuclear staining.
3.3. A1ΔC, but not full length A1, exerts an anti-inﬂammatory effect in
human EC
To evaluate the effect of A1 and A1ΔC on NF-κB activation in human
EC cultures, we stimulated rAd.A1 and rAd.A1ΔC-transduced HUVEC
and HDMEC with 200 U/mL of TNF for 15 min and 2 h, and used
WB to check for IκBα degradation, a surrogate for NF-κB activation.
Non-transduced (NT) and rAd.βgal-transduced EC served as controls.
Overexpression of full lengthA1 in bothHUVEC andHDMEC failed to in-
hibit TNF-mediated IκBα degradation. However, overexpression of the
A1ΔC mutant substantially reduced degradation of IκBα in these cellsFig. 2. Subcellular localization of A1 and A1ΔC overexpressed transgenes in human EC. (A) H
HA-FITC antibody and the mitochondrial probe Mitotracker Red and analyzed by immunoﬂ
that A1, but not A1ΔC, co-localizes with Mitotracker Red, indicating that the C-terminal dom
a cytosolic and nuclear pattern. Representative micrographs of 3 (HUVEC) and 2 (HDMEC)15 min after addition of TNF (Fig. 3A and B). To ascertain that
overexpression of A1ΔC was not simply delaying IκBα degradation,
we performed an extensive time course analysis of IκBα protein levels,
ranging 15 to 90 min following TNF stimulation, in HUVEC. Our data
conﬁrmed that overexpression of A1ΔC in EC inhibits, not simply delays
TNF-mediated IκBα degradation, and even allows faster recovery of
baseline IκBα protein levels (Supplementary Fig. 1).
Downstreamof IκBα degradation,we checked byﬂow cytometry for
the expression of NF-κB-dependent intercellular adhesion molecule 1
(ICAM-1), 16 h following treatment with TNF. Our results indicated
that overexpression of A1ΔC, but not full length A1, in HUVEC and
HDMEC signiﬁcantly inhibit TNF-induced upregulation of ICAM-1
(Fig. 4). Altogether, our data unveil a novel role for A1's C-terminus in
regulating the anti-inﬂammatory function of this protein in human
EC, i.e. the C-terminal domain that anchors A1 to the mitochondria in-
terferes with its ability to inhibit NF-κB activation in human EC. These
results contradict our previous data showing that full length humanUVEC and (B) HDMEC transduced with rAd.A1 and rAd.A1ΔC were double-labeled with
uorescence microscopy with overlay of the different ﬂuorescence colors. Results show
ain of A1 is required to anchor it to mitochondria. In contrast, A1ΔC ﬂuorescence shows
different experiments are shown. Original magniﬁcation 1000×.
Fig. 3. Overexpression of A1ΔC but not full length A1 prevents TNF-induced IκBα degradation in HUVEC and HDMEC. Cell lysates from non-transduced (NT), rAd.A1, rAd.A1ΔC or
rAd.βgal-transduced cells. (A) HUVEC, and (B) HDMEC treated with TNF (200 U/ml) for 15 and 120 min were immunoblotted with anti-IκBα antibody. Results demonstrate that
overexpression of A1 does not affect TNF-induced degradation and loss of IκBα in all EC tested. However, overexpression of A1ΔC inhibits TNF-induced IκBα degradation in both
HUVEC and HDMEC. Immunoblotting with anti-HA and anti-β-actin antibodies was used to conﬁrm transgene expression and correct for loading, respectively. Data shown are
representative of 3 independent experiments for each endothelial cell type.
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BAEC [5]. Given this discrepancy, we wanted to conﬁrm our previous
data using the same BAEC based co-transfection assay and evaluate in
this system the effect of A1ΔC, and also A1ΔBH4, and A1ΔΔ. According-
ly, we co-transfected BAEC with 0.7 μg of pAC empty plasmid or pAC
encoding full length A1 or A1 deletion mutants (A1ΔC, A1ΔBH4, or
A1ΔΔ, together with a NF-κB luciferase reporter (0.7 μg) and a
RSV-βgal reporter (0.3 μg), used to correct for transfection efﬁciency.
Forty-eight hours following transfection, we checked for luciferaseFig. 4. Overexpression of A1ΔC but not full length A1 prevents TNF-induced ICAM-1 upregu
rAd.A1ΔC, or rAd.βgal-transduced HUVEC, and HDMEC 16 h following treatment with T
TNF-induced upregulation of ICAM-1 in all EC tested. However, overexpression of A1ΔC sign
shown are representative of 3 different experiments. Gray shaded areas represent baseline
the shift in ICAM-1 surface expression following TNF stimulation. (B) Bar charts depicting
*p b 0.05, **p b 0.01, and ***p b 0.001 indicate signiﬁcance among different rAd. treatmen
within the same experimental group.and β-gal activities in control non-treated cells, and 7 h after treatment
with 200 U/ml of TNF. Our results conﬁrmed that overexpression of
full-length A1 inhibits TNF-induced activation of the NF-κB reporter in
BAEC (Supplementary Fig. 2A). Inhibition of TNF-induced activation of
the NF-κB reporter was maintained in BAEC transfected with A1ΔC, in-
dicating that thismutant has similar propensity to inhibit NF-κB report-
er activity in bovine EC and IκBα degradation in human EC transduced
with rAd.A1ΔC (Supplementary Fig. 2A). In contrast, deletion of the
BH4 domain from either full length A1 or the A1ΔC mutant abolishedlation in HUVEC and HDMEC. (A) FACS analysis of ICAM-1 surface expression, rAd.A1,
NF (200 U/ml). Our results demonstrate that overexpression of A1 does not affect
iﬁcantly inhibits TNF-induced ICAM-1 upregulation in HDMEC and HUVEC. Histograms
ICAM-1 expression in non-stimulated (NS) EC, while empty black-lined areas indicate
fold increase of median ﬂuorescence intensity ± SEM of 3 experiments performed.
t groups, whereas #p b 0.001 indicates signiﬁcance between NS and TNF-treated cells
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that, akin to Bcl-2, the BH4 domain is essential for A1's anti-
inﬂammatory function, at least in reporter assay based evaluation of
NF-κB activity in BAEC. To further explore the mechanism(s) behind
the discrepancies in A1's ability to inhibit NF-κB luciferase reporter in
BAEC transfected with an A1 plasmid, but not IκBα degradation/NF-κB
activation in human EC transduced with rAd.A1, we used the same
rAd. based transduction protocol to overexpress A1 and A1ΔC in
BAEC, then checked for TNF-induced IκBα degradation. Interesting-
ly, our results fully reproduced our data in human primary EC,
i.e. overexpression A1ΔC but not A1 signiﬁcantly precluded TNF-
induced IκBαdegradation (Supplementary Fig. 2B).Weexcluded differ-
ences in expression levels of the A1 transgene as the reason for discrep-
ancy between transduced (rAd.A1) and transfected (A1 plasmid) in
terms of NF-κB activation. Indeed, either expression method resulted
in comparable levels of HA-tagged A1 protein as shown by Western
blot analysis (Fig. 1 and Supplementary Fig. 2B).
In gaining insight into the physiologic role of A1 in EC's inﬂamma-
tory response, we performed loss of function experiments by trans-
ducing HUVEC with A1-speciﬁc siRNA, achieving >80% knockdown
of A1 mRNA (Supplementary Fig. 3A). A1 knockdown in HUVEC was
particularly signiﬁcant when compared to cells transfected with con-
trol AllStar negative siRNA that showed a 2 to 3 fold increase in A1
mRNA, a likely consequence of the usual toxicity of the transfection
reagents triggering a survival response. None of the commercially
available A1 antibodies was able to detect endogenous A1 protein
levels in HUVEC. However, given the documented short half-life of
the A1 protein (15 min), we believe that A1's protein knockdown
should be at least commensurate to its mRNA knockdown, even if
we cannot formally prove it [24]. On the sole basis of mRNA levels,
A1mRNA knockdown did not impact IκBα degradation following
TNF (Supplementary Fig. 3B), which could suggest that A1 is not a
physiologic regulator of NF-κB activation. This contrasts with knock-
down of the NF-κB inhibitory gene A20 that causes prolonged NF-κB
activation with delayed recovery of IκBα protein levels in different
cell types [25], including EC (data not shown). These data support
our gain of function experiments in rAd.A1 transduced EC, as they in-
dicate that full length A1 does not have a signiﬁcant physiologic role
in down-regulating NF-κB activation in these cells.
3.4. Full length A1 and A1ΔC equally protect human EC from
staurosporine-induced cell death
Classically, A1 is described as an anti-apoptotic Bcl-2 family member.
However, several reports challenge this statement, demonstrating that
A1 could be anti-apoptotic, or pro-apoptotic, depending on cell type
and apoptotic stimulus [26–28]. In a microvascular endothelial cell line,
A1 predominantly localized at the mitochondrial membrane, where it
functioned to inhibit Cytochrome c release and Caspase 9 activation,
maintaining mitochondrial transmembrane potential and promoting
temporary survival of these cells in response to TNF [22]. To examine
the contribution of A1 mitochondrial anchoring to its cytoprotective
properties in human EC derived from primary cell cultures, we checked
for the effect of A1 and A1ΔC overexpression in HUVEC and HDMEC on
STS-induced cell death. Our results showed that both A1 and A1ΔC sig-
niﬁcantly protect HUVEC andHDMEC from STS-induced cell death, com-
pared to control NT and rAd.βgal transduced EC (Fig. 5; n = 3). These
results indicate that localization of A1 to mitochondria is not required
for its cytoprotective function in primary human EC cultures. These re-
sults are completely concordant with our data in BAEC transfected with
A1 and A1 mutants expression plasmids (Supplementary Fig. 2C).
4. Discussion
A1/Bﬂ-1 is classically described as a TNF-inducible, NF-κB-dependent,
anti-apoptotic Bcl-2 family member in EC [4,5,22]. We had previouslyshown that A1 also exerts anti-inﬂammatory effects in BAEC by inhibiting
NF-κB activation [5]. In this study, we performed a structure–function
analysis of A1 in order to delineate the role of its C-terminal domain
upon its NF-κB inhibitory and cytoprotective effects in EC, and extended
this study to human EC.
Using co-immunoﬂuorescence staining,we showed that full lengthA1
mostly localizes to mitochondria, which conﬁrms that the amphipathic
C-terminus of A1 drives its localization to this organelle, tempering
some of the controversy about A1's cellular localization [11]. This result
is consistent with data reporting that A1 and other anti-apoptotic Bcl-2
family members preferentially localize to mitochondria, where they di-
rectly (Bcl-2, Bcl-xL), or indirectly (A1/Bﬂ-1 through binding to Bid and
tBid) [29] inhibit the activation of pro-apoptotic Bcl-2 family members
(Bax) [30,31].
In contrast, A1ΔC was excluded from mitochondria, showing a
nuclear and cytosolic pattern, similar to that described in MCF-7 cells
overexpressing a Bﬂ-1 deletion mutant lacking the C-terminal domain
[29]. While we expected cytosolic expression for a protein devoid of
its C-terminus, we questioned the nuclear staining of A1ΔC. ByWestern
blot analysis, we demonstrated that only a negligible fraction of A1ΔC is
detected within the pool of soluble nuclear proteins, suggesting that
A1ΔCwasmainly cytoplasmic. Even though, a fraction of the A1ΔC pro-
tein may still be attached to the inner nuclear membrane, which would
explain the peri-nuclear distribution that we detect by IF (Supplemen-
tary Fig. 4A). In fact, deletion of the A1 C-terminus should not result in
a nuclear localization sequence, contrastingwith the short splice variant
of human A1 (Bﬂ-1S), that in addition to lacking the C-terminus
domain, incorporates a 56-bp exon-II into its sequence that creates a
nuclear localization sequence [32]. Using Bﬂ-1S speciﬁc primers, we
demonstrated the presence of mRNA encoding for this short variant of
A1 in HUVEC, although its levels were less abundant at baseline than
that of full length A1, but alike A1 increased after addition of TNF
(Supplementary Fig. 4B).
Next, we evaluated the effects of A1 and A1ΔC on NF-κB activation
in human EC, using TNF-mediated IκBα degradation and ICAM-1
upregulation as surrogates. Surprisingly, full length A1 did notmaintain
its NF-κB inhibitory function in human EC, similar to our data in human
RPTEC [6]. Furthermore, A1 silencing, at least as determined by mRNA
knockdown, did not amplify TNF-induced pro-inﬂammatory responses
of EC, suggesting that full lengthA1 does not inﬂuence inﬂammatory re-
sponses in EC. This is consistentwith the absence of a pro-inﬂammatory
phenotype in mice with a knockdown of the mouse A1a isoform, as
these mice only suffer from enhanced neutrophil apoptosis [33]. In
striking contrast, A1ΔC showed an anti-inﬂammatory function in
HUVEC and HDMEC, similar to what we had reported in HUVEC trans-
duced with a rAd.Bcl-2 adenovirus lacking its transmembrane domain
[8,34]. Inhibition of NF-κB signaling only happenswhen A1 loses its am-
phipathic C-terminal domain and/or gets freed from the mitochondria.
Additional experiments are underway to test this hypothesis. Intrigu-
ingly, these results partially disagree with our NF-κB reporter assays
in BAEC, where full length A1 and A1ΔC were as effective in inhibiting
TNF-induced NF-κB reporter activity. Discrepancy between results
obtained in BAEC and human EC were not due to differences in the
expression level of the transgene but are likely related to differences
in experimental systems used (reporter assays vs. direct probing of
components of the NF-κB signaling pathway in rAd. transduced EC),
since rAd.A1 and rAd.A1ΔC transduced BAEC gave similar results to
what we reported in primary EC (Supplementary Fig. 2B).
On the basis of NF-κB reporter assays, we also have evidence that
the BH4 domain of A1/Bﬂ-1 is responsible for its NF-κB inhibitory ef-
fect. This result agrees with what we had already described for the
prototypic Bcl-2 and Bcl-xL family members [8]. Future work in the
laboratory aims to conﬁrm this ﬁnding in human EC, and in systems
evaluating the EC's own NF-κB machinery.
In addition, we showed that full-length A1 protected EC from cell
death triggered by the pan-protein kinase inhibitor, staurosporine.
Fig. 5. Full-length A1 and A1ΔC mutant protect HUVEC and HDMEC from cell death induced by staurosporine (STS). Non-transduced (NT), rAd.A1, rAd.A1ΔC, and
rAd.βgal-transduced. (A) HUVEC and HDMEC were treated with STS (100 nM) for 6 h, then labeled with propidium iodide. Apoptosis was evaluated by FACS analysis of DNA
content. Data shown are representative of 3 independent experiments. The percentage of cells undergoing cell death, as evidenced by DNA b 2N (subG1 phase) is reported. (B) Bar
chart representation of mean percentage of cell death ± SEM of the 3 experiments performed. *p b 0.05, **p b 0.01, and ***p b 0.001 indicate signiﬁcance among different treatment
groups, i.e. non-transduced (NT) EC and EC transduced with different rAd. #p b 0.05, ##p b 0.01, and ###p b 0.001 indicate signiﬁcance between non-stimulated (NS) and
STS-treated HUVEC and HDMEC within the same experimental group.
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CHX/TNF-induced apoptosis [22,35] emphasizes a broader anti-apoptotic
effect of this protein in EC. This result is important because thecytoprotective effect of A1 is far from ubiquitous. Indeed, while A1 main-
tains its anti-apoptotic function in skeletal and cardiac myocytes and in
several cancer cells [36–38], it promotes TNF-induced apoptosis of spinal
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ly, “anti-inﬂammatory” A1ΔC equally protected EC from cell death, prov-
ing that mitochondrial localization is not required for the pro-survival
function of A1 in EC. This result is analogous to data showing that
C-terminus deletion mutants of human A1/Bﬂ-1 (A1ΔC and Δα9-Bﬂ-1)
were still able to protect FL5.12 pro-B cells, and NIH-3T3 cells from STS
and serum-starvation-induced apoptosis, respectively [11,26]. However,
this result contrasts with results obtained in themurine B cell lymphoma
cell line, WEHI 231, where deletion or mutation of the C-terminus of A1
eliminated its ability to protect these cells from etoposide-induced cell
death [24]. All these evidence stress cell type speciﬁc functions of
full-length A1/Bﬂ-1 and its C-terminus-deletion mutant.
We and others have shown that the anti-apoptotic function of A1 and
prototypic Bcl-2 familymembers in EC and other cell types relies on intact
BH1, BH2, and especially BH4 domains [8,12,14,15]. In the case of A1/
Bﬂ-1, an intact BH3 domain that associates with pro-apoptotic Bcl-2 fam-
ilymembers, Bid andBim, is also required [23,24].We established inBAEC
transfected to express full lengthA1ormore importantly anA1ΔCmutant
where the BH4 domain was deleted (A1ΔBH4, and A1ΔCΔBH4), that
the BH4 domain of A1 and A1ΔC was required for both their anti-
inﬂammatory and anti-apoptotic functions. We presume that speciﬁc
binding partners and/or functions associated with this domain support
A1/A1ΔC cytoprotective function without necessarily requiring its an-
choring to themitochondrial membrane.We recognize that this assump-
tion challenges previously established concepts, at least in EC. Hence,
future studies are underway to conﬁrm these results in human EC,
check their validity on the cell ownNF-κBmachinery, and potentially dis-
cover their molecular basis.
In conclusion, our data exposes an important regulatory role for
the amphipathic C-terminal domain of A1 in human EC. This domain is
essential for A1 anchoring to the mitochondrion, but is not a pre-
requisite for its cytoprotective function in EC. The C-terminal domain of
A1, or alternativelymere anchoring of this protein atmitochondria inter-
feres with its anti-inﬂammatory function in EC. This function only
emerges when the C-terminus of A1/Bﬂ-1 is deleted, releasing it from
themitochondrion. Futurework aims to determinewhether this domain
is ever cleaved under physiologic or pathologic conditions, in response
to select EC activators, to transform A1 from a sole anti-apoptotic to a
multi-functional anti-apoptotic and anti-inﬂammatory molecule. The
fact that the C-terminal domain of A1 is also involved in its ubiquitination
and protein turnover supports such an endeavor [24,26] that could rede-
ﬁne A1's role in modulating EC homeostasis and phenotype. Ultimately,
A1-ΔC-based EC therapies have the potential to treat vascular inﬂamma-
tion while providing a survival advantage.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.bbamcr.2013.03.001.Acknowledgements
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